Radiopharma developers Actithera and Nuclidium secured venture capital investment as part of a broader funding wave encompassing Varda and Renasant, alongside public offerings from Rhythm, Cogent, Soleno, and Milestone. This financial influx supports innovations in diagnostic and therapeutic radiopharmaceuticals, reflecting investor confidence in the sector's growth prospects amid expanding clinical applications.